Changing the enzalutamide form from a capsule to a tablet improves the adherence of medicine intake: A case of a significant decrease in the prostate‐specific antigen level and improvement in radiographic findings

INTRODUCTION: In June 2018, enzalutamide began to be sold in a tablet form in Japan and Germany. We herein report the case of an improvement in prostate cancer progression due to changing enzalutamide dosage form from a capsule to a tablet. CASE PRESENTATION: A 76‐year‐old man was initially referred...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawahara, Takashi, Ninomiya, Sahoko, Miyoshi, Yasuhide, Yao, Masahiro, Uemura, Hiroji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292163/
https://www.ncbi.nlm.nih.gov/pubmed/32743396
http://dx.doi.org/10.1002/iju5.12062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292163/
https://www.ncbi.nlm.nih.gov/pubmed/32743396
http://dx.doi.org/10.1002/iju5.12062

Ejemplares similares